A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

In a single-center, prospective, phase II study (ClinicalTrials registration number: \[to be filled in\]) initiated by our center to evaluate the safety and preliminary efficacy of short-course radiotherapy followed by sequential CAPOX chemotherapy combined with serplulimab and bevacizumab as total neoadjuvant therapy for MSS-type mid-low locally advanced rectal cancer, patients with mid-low MSS-type locally advanced rectal adenocarcinoma were enrolled. They received short-course radiotherapy combined with CAPEOX, serplulimab, and bevacizumab as preoperative total neoadjuvant therapy. It is an

Trial Details

NCT ID
NCT07347951
Phase
PHASE2
Sponsor
First Affiliated Hospital of Wenzhou Medical University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Short-course radiotherapy
  • CAPOX chemotherapy
  • Targeted therapy with bevacizumab
  • Serplulimab immunotherapy
Locations (sample)
  • Wenzhou, Zhejiang, China|27.99942,120.66682

Key Eligibility Criteria

  • Patients who have a desire to preserve the anus and are willing to receive the entire course of neoadjuvant therapy.
  • Aged between 18 and 75 years, with no gender restrictions.
  • Diagnosed via pelvic MRI and rectoscopy with a tumor located ≤10 cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes conf…
  • Histologically diagnosed with rectal adenocarcinoma; genetic testing indicates MSS or MSI-L, or immunohistochemistry of tumor biopsy indicates pMMR…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →